Ashley Gallagher, Associate Editor

The National Institute of Health’s grant funds a phase 2 clinical trial of doxycycline in a large group of individuals with the 2 conditions who are smokers or used to smoke.

Results show possible impact of using Janssen Pharmaceuticals’ ibrutinib in the front-line setting, providing additional data on chronic lymphocytic leukemia therapies.

From newsworthy moments to groundbreaking research, these are the most popular articles in the zoster space, published on Pharmacy Times® during 2022.

Intravenous tocilizumab (Actemra; Genentech) has been approved for the treatment of COVID-19 in individuals who are hospitalized and receiving systemic corticosteroids and supplemental oxygen.

Calcitriol may offer protection from the harmful effects of the chemical in drinking water, analysis shows.

The protein is vitally important and could be a prognostic indicator and potential therapeutic target.

TD2 remission is defined as a hemoglobin A1C level of less than 6.5% at least 1 year after stopping medication, investigators say.

From newsworthy moments to groundbreaking research, these are the most popular articles in the cholangiocarcinoma space, published on Pharmacy Times® during 2022.

Recommendations for the management of bile duct cancer benefit authorities, patients, and physicians, but investigators say more research is needed.

From newsworthy moments to groundbreaking research, these are the most popular articles in the intravenous immunoglobulin space, published on Pharmacy Times® during 2022.

Investigators hope findings of study in mice help improve treatment for individuals with acute kidney injury.

Although physical activity and the practice of being present in the moment are associated with many benefits, analysis shows that neither led to measurable improvements in brain health.

Investigators establish that audio and/or facial video features have been most analyzed by machine learning, followed by electroencephalography signals.

Merck and Moderna’s adjuvant melanoma treatment shows reduced risk of recurrence or death by 44% compared with pembrolizumab alone.

E7777 is an engineered interleukin-2-diphtheria toxin fusion protein that is a purified and more bioactive formulation of Ontak, which the agency previously approved.

A deficiency in the supplement is thought to be associated with early activation of the hypothalamic-pituitary gonadal axis, obesity, and stunting.

The updated recommendations during a surge in cases emphasize the need to enhance emergency readiness daily to not interrupt continuous care of children’s mental and physical well-being.

Despite the increasing approval of neurological medications, just a small percentage of individuals are using them because of skyrocketing out-of-pocket expenses.

Relatives who attend low-intensity coaching and monitoring meetings increase individuals’ ability to manage the disease.

Data show that despite declines in visit rates to federally qualified health centers, patients with psychological disorder diagnoses during COVID-19 did well when telemedicine was available.

The investigational drug is a monoclonal antibody with a high affinity and specificity for cancer-specific plectin, a cell surface protein that correlates with aggressive tumors and poor prognosis.

Investigators model 2 hypothetical cities as interconnected networks with a combined population of 100,000 bisexual, gay, and other men who have sex with men.

A diverse population and financial obstacles present unique challenges for pharmacists in Hawaii.

Pharmacists can coordinate education programs for patients to normalize quality of life and minimize infusion-related pain.

GSK3036656 demonstrates early bactericidal activity with a low, once-daily oral dose after 14 days of treatment.

The implementation of negative control outcomes and a complementary cohort demonstrate an estimated beneficial effect that associated with an individual’s overall health.

Study results show that patients with moderate or severe immune suppression should be considered a priority for additional vaccine doses and risk-reduction strategies.

Investigators believe the findings can refine predictions, after independent evaluation, by identifying different modes of genetic alteration.

Pharmacists can coordinate educational programs for patients to normalize quality of life and minimize infusion-related pain.

The seasonal flu vaccine should be prioritized for those with SCN1A-positive Dravet syndrome, because of the likelihood of severe neurological symptoms and complications.